Showing results (141-150 of 175) with videos related to
Sort By:
Pageof 18
Annals of Hematology|April 25, 2024
Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practiceAleksander Chojecki, Danielle Boselli, Allison Dortilus, et al.Blood Advances|September 11, 2020
ACVR1/JAK1/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trialStephen T Oh, Moshe Talpaz, Aaron T Gerds, et al.Clinical Lymphoma, Myeloma & Leukemia|November 8, 2024
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With MomelotinibClaire N Harrison, Ruben Mesa, Moshe Talpaz, et al.Transplantation and Cellular Therapy|September 13, 2024
Real-World Analysis of Barriers to Timely Administration of Chimeric Antigen Receptor T Cell (CAR T) Therapy in Diffuse Large B-cell LymphomaBei Hu, Rakhee Vaidya, Ferdous Ahmed, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2011
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNetTiziano Barbui, Giovanni Barosi, Gunnar Birgegard, et al.Hemasphere|November 1, 2023
Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 TrialsJean-Jacques Kiladjian, Alessandro M Vannucchi, Aaron T Gerds, et al.Contemporary Clinical Trials|December 18, 2023
Advancing Inclusive Research (AIR) Site Alliance: Facilitating the inclusion of historically underrepresented people in oncology and ophthalmology clinical researchGregory A Vidal, Patricia Chalela, Andrea N Curry, et al.Cancer Cell|July 2, 2021
Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancerAlfredo Addeo, Pankil K Shah, Natacha Bordry, et al.The Lancet. Haematology|January 27, 2020
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 studyJean-Jacques Kiladjian, Pierre Zachee, Masayuki Hino, et al.Blood|October 28, 2017
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamideClaire N Harrison, Adam J Mead, Anesh Panchal, et al.Pageof 18